Published in final edited form as:

Semin Nucl Med. 2016 March ; 46(2): 109–118. doi:10.1053/j.semnuclmed.2015.10.010.

Novel Approaches to Thyroid Cancer Treatment and Response Assessment

Ravinder K. Grewal, MD¹, Alan Ho, Md, PhD², and Heiko Schöder, MD¹

¹Molecular Imaging and Therapy Service, Department of Radiology

²Head and Neck Medical Oncology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

The incidence of thyroid cancer has been on the rise. After total thyroidectomy of well differentiated thyroid tumors with intermediate or high-risk features on pathology, radioiodine remains one of the mainstays as the standard therapy for thyroid remnant ablation as well as treatment of metastatic disease. SPECT/CT, a relatively newer modality, has shown to play a pivotal role predominantly in the post-therapy setting by changing the risk stratification of patients with thyroid cancer. In the case of radioiodine failure, other modalities such as FDG PET/CT have been shown to provide prognostic information in terms of metabolic activity and external beam radiation therapy, thereby playing a role in disease management. The role of newer redifferentiation drugs has been evaluated with the use of I-124 PET/CT.

Differentiated thyroid cancer accounts for approximately 95% of all thyroid carcinomas; of these, approximately 85-90% are papillary, approximately 10% are follicular, and approximately 3% are Hurthle cell carcinomas or tumors with poorly differentiated histology.¹ The most recent American Thyroid Association guidelines (ATA, 2009) recommend total thyroidectomy for tumors greater than 1 cm and possible lobectomy for tumors $\leq$ 1 cm.¹ However, a recent retrospective analysis of over 3,600 patients with differentiated thyroid cancer found that tumors 1-2 cm have the same disease-specific survival and recurrence-free survival compared with tumors $\leq$ 1 cm when omitting tumors with aggressive features such as nodal metastatic disease and extrathyroidal extension.² Similarly, DeGroot et al. reported a decreased risk of death and risk of recurrence for tumors $>$ 1 cm in a group of 269 patients with papillary thyroid cancer treated with extensive initial surgery as well as post-operative I-131 ablation.³ The frequency of nodal metastases was highest in papillary thyroid cancer (61%), whereas Hurthle cell carcinomas showed a 33% incidence of distant metastases in a retrospective review of 1,038 consecutive patients with differentiated thyroid cancer treated over a period of 55 years.⁴ Although papillary thyroid

Address for correspondence: Ravinder K. Grewal, MD, Molecular Imaging and Therapy Service, Department of Radiology, 1275 York Ave, Box 77, New York, NY 10065.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cancer (PTC) and follicular thyroid cancer (FTC) are two distinct histological types, they have been studied collectively under the header of 'differentiated thyroid cancer.' A retrospective study of 760 differentiated thyroid cancer patients (589 PTC and 171 FTC) showed marked differences in prognostic factors in the two groups. Patients with PTC are typically younger than 50 years of age and have smaller tumors and a higher incidence of lymph node metastases, multicentricity, and extrathyroidal extension. Patients with FTC show a higher incidence of distant metastatic disease and more frequently receive radioiodine. The independent factors predicting poor prognosis for the PTC group were age 50 years, tumors 3.5 cm, extrathyroidal extension, and incomplete resection. In the FTC group, these factors were age 50 years and incomplete resection of distant metastatic disease.⁵ Other studies have concluded that, stage for stage, the prognosis is similar for papillary and follicular thyroid cancers in general.^{6,7} Other histologic subtypes of papillary thyroid cancer, such as columnar cell variant, tall cell variant, and diffuse sclerosing variant; more aggressive variants of follicular thyroid cancer; and poorly differentiated aggressive histologies have a worse prognosis—these histologies typically exhibit aggressive histologic features such as extrathyroidal extension, vascular invasion, and tumor necrosis.⁸ Recent ATA guidelines propose a three-level stratification (low, intermediate, and high risk) based on the presence or absence of aggressive histologic features, presence of local or distant metastases, and imaging features on post-therapy scans.¹

In recent years, it has become clear that many thyroid cancers are driven by oncogenic mutations. For instance, approximately 45% of papillary differentiated thyroid cancers harbor BRAF V600E mutations; other mutations such as RAS or RET/PTC mutations are less frequent.^{9,10} RAS mutations are more common in poorly differentiated thyroid cancers.¹¹ Thyroid cancers bearing the BRAF V600E mutation show significantly higher FDG avidity compared to BRAF wild type tumors.¹² These data shed interesting light on the connection between tumor biology and imaging features and may also be helpful in designing clinical trials, which will be discussed later.

Treatment Design and Role of Conventional Imaging

After surgical resection of the primary tumor, radioactive iodine (RAI, I-131) is used in the majority of patients¹³ for both thyroid remnant ablation and treatment of expected or proven locoregional or distant metastases.¹⁴ Metastatic thyroid cancers of follicular cell origin retain, to varying degrees, the ability of normal thyrocytes to take up and retain iodide; this depends critically on the presence of functioning cell membrane-based sodium iodine symporters (NIS),¹⁵ which are active in approximately 80% of well differentiated thyroid cancers. Few other cell types (such as salivary glands, lactating breasts, stomach, and small intestines) possess the ability to concentrate iodide; therefore, I-131 is a selective, targeted approach for delivering tumoricidal doses of radiation to thyroid tumors. I-131 can be particularly effective for radioiodine-avid small volume (< 1 cm) micronodular lung metastases from well differentiated thyroid cancer, as shown in a study of 444 patients.¹⁶ The efficacy of I-131 treatment, however, is limited in patients with larger tumors, which are nevertheless often treated repeatedly with I-131.¹⁶⁻²⁰ Not all patients with thyroid cancer need to be treated with radioiodine. The recent ATA guidelines recommend radioiodine therapy only for intermediate and high-risk patients with known distant metastases, gross

extrathyroidal extension (regardless of tumor size), or primary tumors > 4 cm. Radioiodine ablation is recommended for selected patients with primary tumors measuring 1-4 cm and clinico-histologic features predicting intermediate to high-risk of tumor recurrence.¹

In order to achieve sufficient iodine uptake into tumor cells, RAI ablation or therapy requires elevated levels of thyroid-stimulating hormone (TSH). TSH stimulation can be accomplished by thyroid hormone withdrawal or by intramuscular injection of rh-TSH (Thyrogen®). Serum TSH levels > 30 Mu/L can be obtained in > 90 patients with either method of preparation, both of which are effective.²¹⁻²³ Following appropriate stimulation, a pre-therapy scan with low activities of I-123 or I-131 can be performed to quantify the percentage of neck uptake and is recommended when scan findings are expected to change management (e.g., high residual uptake of iodine in the neck or visualization of unsuspected metastatic disease may prompt changes in the amount of I-131 chosen for ablation or treatment¹). ATA guidelines recommend (based on expert opinion rather than hard data) that low activities of I-131 (1-3 mCi) or I-123 (1.5-3 mCi) be used for pre-therapy scans and therapeutic I-131 activities be administered within 72 hrs of this diagnostic procedure.¹ A SPECT/CT prior to RAI treatment remains of limited use. Occasionally, this test may detect iodine-avid neck node metastases, depending on the extent of surgical resection. However, today, many surgeons will perform a preoperative neck ultrasound and will then resect all nodes that appear suspicious. Any remaining (presumably small) iodine-avid neck nodes will not change management, and ablation with RAI will proceed regardless. Occasionally, a pre-treatment SPECT/CT may also detect (unexpected) distant metastases, which may prompt selection of a higher treatment activity. Nevertheless, a negative pre-treatment SPECT/CT may potentially give false comfort, as the probability for detecting distant disease is significantly limited by the low activity used for pre-treatment scans. Studies such as the following should therefore be interpreted in this context. In a prospective study of 320 patients, pre-ablation iodine SPECT/CT changed the risk stratification in 15% patients as compared to recurrence risk estimation based on histopathology alone. Regional metastases were noted in 35% and distant metastases in 8% of patients. The authors reported that this led to a change in clinical management in about 30% of patients.²⁴ However, these changes largely pertained to changes in the amount of RAI administered, and eight patients with “unexpected” bulky neck nodes were referred back to surgery. The latter should be a rather unusual occurrence when surgeons take advantage of preoperative ultrasound and perform a thorough intraoperative exploration of the tracheo-esophageal groove and neck.

Three approaches to determine the amount of RAI for ablation and therapy are widely practiced: administration of a fixed empiric activity, calculation of a maximum tolerated activity (using dose constraints to blood/bone marrow and lung), and quantitative tumor lesional dosimetry.¹⁴ In low-risk patients, activities between 30-100 mCi I-131 are often administered, which yield similar rates of remnant ablation.²⁵⁻²⁸ In patients with primary tumors showing aggressive histologic features, such as tall cell, columnar, or insular carcinoma, higher activities (100-200 mCi) are recommended.¹ The maximum tolerated radiation-absorbed dose (MTRD), defined as 200 rads (cGy)²⁹ to blood, can be exceeded in a significant number of patients undergoing empiric treatments with arbitrary or fixed amounts of I-131. In a retrospective study of 328 patients, a fixed empiric treatment with 200 mCi I-131 would have exceeded the MTRD in 22% of patients 70-79 years old and 38%

of patients aged 80 years or older.³⁰ In another study, empiric treatment with 100 mCi, 150 mCi, 200 mCi, 250 mCi, and 300 mCi of I-131 would have exceeded the MTRD in < 1%, 5%, 11%, 17%, and 22%, respectively.³¹ In part, this is related to the fact that many older patients exhibit somewhat compromised renal excretory function. Lesional dosimetry, performed with diagnostic I-124 PET/CT, is the most sophisticated, albeit laborious and time-consuming approach for treatment planning; its role will be discussed later in this review.

Following I-131 therapy, post-therapy scans are performed approximately 3-10 days after the RAI administration. These post-treatment scans may show additional metastases in 10-26% patients when compared to pre-treatment imaging,^{32,33} although higher numbers were also reported in some studies. Extensive disease noted on post-treatment scans may alter the clinical stage in about 10%, and clinical management in 10-15% of patients.³²⁻³⁴ In contrast to the pre-treatment setting, a SPECT/CT may provide meaningful and actionable information in the post-treatment setting. In a study of 148 consecutive patients (109 post-surgical and 39 with recurrent/metastatic disease), SPECT/CT provided clear classification of iodine uptake as benign or malignant, thus eliminating the need for additional cross-sectional imaging in 20% of patients. SPECT/CT better characterized clearly metastatic disease in the neck as well as distant metastases in lung, liver, and bone.³⁵ In another study of 57 patients, SPECT/CT of the neck determined nodal involvement more accurately than did planar imaging and altered clinical management in approximately one quarter of patients.³⁶ In another study of 151 patients, post-therapy SPECT/CT of the neck showed lymph node metastases in 26% of T1b cancers and 22% of the microcarcinoma group.³⁷ In a retrospective study of 147 differentiated thyroid cancer patients, SPECT/CT improved detection and localization of I-131 in nodal and distant metastases as compared to whole body planar imaging and changed clinical staging in 9/147 patients (6.1%) and therapy planning in 3/147 patients (2%).³⁸

The anti-tumor effect of I-131 depends on the amount of RAI that can be delivered successfully to the target lesion ("lesional activity").³⁹⁻⁴² Without "lesional dosimetry" to quantify the amount of RAI accumulating in a given disease site (thus allowing some prediction of the efficacy of RAI treatment), the amount of I-131 administered for metastatic disease must be determined empirically or using whole body dosimetry. The latter yields a maximum tolerated activity (MTA), defined as the highest activity that can be administered without toxicity to bone marrow and lungs⁴³ (MTA is the activity of I-131 that will result in a dose of 200 rads to blood and in a retained activity of 80 mCi in the lungs at 48 hours—the latter is usually relevant only in patients with diffuse lung metastases). However, there may be considerable heterogeneity of RAI uptake among lesions. This can only be addressed by lesional dosimetry with I-124 PET/CT, which permits quantification of iodine uptake in each disease site and thus individualized, patient-specific treatment planning.⁴⁴ Maxon et al. determined that a dose of at least 8,000 rads is needed to achieve complete destruction of thyroid cancer metastases and at least 30,000 rads for the thyroid remnant.⁴¹ Except for lesional dosimetry, no other techniques exist to predict which patient with metastatic thyroid cancer will respond to RAI therapy. Therefore, in practice, many patients will be treated repeatedly with RAI, using "empirical" activities; however, this may well be ineffective and could cause potential morbidity.^{45,46}

External beam radiotherapy (EBRT) is rarely employed in the management of differentiated thyroid cancer. However, it is a meaningful adjuvant modality in patients > 45 years with gross unresectable tumor or significant extrathyroidal extension in whom further surgery or RAI would not be effective.¹ In an earlier study from our institution, EBRT provided effective locoregional control in a select group of locally advanced or recurrent non-anaplastic thyroid cancers, with 2- and 4-year overall locoregional control rate of 86% and 72%, respectively.⁴⁷ In a more recent study with 66 patients, these data were confirmed: EBRT alone or in conjunction with chemotherapy proved safe and effective, providing locoregional control in 90% of patients undergoing concurrent chemoradiotherapy and >85% locoregional control in patients with no metastases.⁴⁸

PET/CT Imaging with Iodine-124 and F-18 FDG

I-124 is a positron emitter with a half-life of 4.2 days; about 22% of the disintegrations produce positrons of relatively high energies as well as high-energy gamma and x-rays.^{49,50} Most published studies using I-124 PET or PET/CT include only small numbers of patients due to logistical challenges and expense of I-124. Therefore, conclusions remain somewhat preliminary. Nevertheless, it has been shown convincingly that I-124 PET/CT is more sensitive in detecting metastatic disease than gamma camera imaging with I-131⁵¹⁻⁵⁴ (Figure 1). For instance, in a study in 25 patients, I-124 PET identified 50% more sites of disease than the pre-treatment (“diagnostic”) scan with I-131 dosimetry scans in 32% of patients.⁵² I-124 PET/CT also enables lesional dosimetry. In a retrospective study of 34 patients, I-124 PET allowed for reliable volume estimation (>0.80 ml) in 59 lesions in 17 patients.⁵⁵ In another study, I-124 PET lesional dosimetry was used to calculate the amount of RAI needed to achieve doses of 100 Gy to all metastases without exceeding dose of 2 Gy to the blood; I-124 PET led to a change in management in 25% of patients.⁵⁶ In another study, 15 of 30 patients with known metastatic disease showed no I-124 uptake on serial scans (4, 24, 48, and 72 hours), despite sufficiently high TSH levels, suggesting that these lesions would also be refractory to I-131 treatment⁵⁷. A smaller study in 12 patients disagreed with this conclusion and suggested that I-124 PET should not be used in isolation to prevent treatment with I-131.⁵⁸ However, it should be realized that uptake of I-131 alone on post-treatment scans is not sufficient for response, unless the local dose from accumulated iodine is tumoricidal. The probability of achieving tumoricidal doses is best predicted by I-124 PET.

An inverse relationship between FDG avidity and radioiodine uptake (originally described by Feine as the ‘flip-flop’ phenomenon,⁵⁹ (Figures 2, A and B) is often seen in metastatic thyroid cancer lesions; increased FDG uptake is generally associated with decreased disease-specific survival.⁶⁰ In general, FDG avidity increases and iodine avidity decreases, as tumors or metastases de-differentiate, which is associated with increasing disease aggressiveness, refractoriness to RAI therapy, and poorer prognosis.⁶¹ A histopathologic study also showed that the majority of metastases in patients with radioiodine-refractory, FDG-positive metastases were of histologically aggressive subtypes.⁶² However, the “FDG/iodine flip-flop” is not an all-or-none phenomenon. On one extreme side of this spectrum are anaplastic carcinomas, which are reliably FDG-avid and in which the intensity of FDG uptake is correlated with survival.⁶³ On the other end of the spectrum are metastases from

well-differentiated papillary carcinomas that show intense iodine uptake, but no FDG uptake. In patients with truly advanced disease, there is usually a spectrum of metastatic lesions—some more or only iodine-avid, and some more or only FDG-avid. The presence, intensity, and extent of FDG-avid disease provides prognostic information, helps guide therapy (even high activities of RAI have little or no therapeutic effect on FDG-avid metastases⁶⁴), and may aid in treatment monitoring (a decline in FDG uptake may indicate a response to novel targeted drugs in patients with advanced thyroid cancer). The prognostic value of FDG PET in advanced thyroid cancer was well documented in a classic study with 125 patients in whom survival was lower among patients with FDG-positive disease as compared to patients without FDG avid lesions: Patients with a volume of FDG-avid disease > 125 ml had a significantly shorter survival.⁶⁵ FDG PET may also help in the management of patients with differentiated thyroid cancer presenting with elevated Tg levels but a negative I-131 scan; in this setting, FDG PET may be most useful when Tg levels are greater than 10 mcg/ml.⁶⁶⁻⁶⁹ Beyond the volume of FDG-avid disease, the intensity of FDG uptake in metastatic lesions, measured as SUV, further refines the prognostic information of this test. In a retrospective study of 400 thyroid cancer patients, FDG SUV and number of FDG-avid lesions were correlated with poor survival. Among all patients, those with local neck disease had the best survival, those with regional metastases (e.g., in supraclavicular or mediastinal nodes) fared slightly worse, and patients with distant metastases had the lowest overall survival⁶⁷ (Figure 3, A and B). For all of these aforementioned reasons, post-operative FDG PET is recommended to be performed routinely in thyroid cancer patients with aggressive histologies in order to establish a reference stage for future follow-up. In this retrospective study of 20 patients with a total of 86 lesions, FDG PET was more sensitive than post-ablation radioiodine scan for detection of lesions (69% versus 59%).⁷⁰

Discoveries in Thyroid Cancer Biology Provide a Rationale for Novel Targeted Therapies

Oncogenic signaling diminishes iodide avidity in RAI-refractory (RAIR) thyroid cancer

Recent advances in molecular targeted therapies have helped us in better understanding those patients who may benefit from I-131 therapy and identify other patients who may benefit from new therapeutic approaches.⁷¹ Patients with RAI-refractory (RAIR) metastatic tumors that either lack or lose the ability to trap iodide possess a worse prognosis: the 10-year survival of patients with metastatic lesions retaining RAI avidity is approximately 60%, but only 10% for patients with RAIR disease.¹⁶ Over the past decade, multi-targeted tyrosine kinase inhibitors (TKIs), which are thought to block tumor angiogenesis by inhibiting multiple receptor tyrosine kinases (e.g., VEGFR and PDGFR), have emerged as new treatment modalities for metastatic thyroid cancer. Based on these data, the Food and Drug Administration (FDA) approved the TKIs Sorafenib and Lenvatinib for the treatment of RAIR thyroid cancer^{72,73} (Figure 4). The challenge of these therapies is the need to maintain continuous drug dosing and manage the accompanying drug toxicities in order to realize clinical benefit. In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial with Sorafenib in progressive RAIR differentiated thyroid cancer, Sorafenib improved progression-free survival compared to placebo (10.8 months with Sorafenib vs. 5.8 months with placebo).⁷² In another multicenter phase 3 randomized, double-blind study of patients

with progressive thyroid cancer comparing Lenvatinib versus placebo, the median progression-free survival was 18.3 months in the Lenvatinib group versus 3.6 months in the placebo group. There were four complete responses (64.8%) in the Lenvatinib group and 1.5% in the placebo group.⁷³ Of note, in the phase 3 trials, the rate of dose interruption, reduction, and discontinuation was significant for both Sorafenib and Lenvatinib, which may undermine the benefits of these therapies.^{72,73} For these patients, developing a novel strategy of restoring the efficacy of I-131 would provide a therapeutic alternative for managing metastatic disease with a discrete period of treatment, and potentially delay the need to initiate continuous drug therapy.

Current experimental strategies aim to target oncogenic signaling pathways that diminish iodide avidity in thyroid cancer. For instance, activation of the mitogen-activated protein kinase (MAPK) signaling pathway (RET - RAS - RAF - MEK - ERK) is a central oncogenic event for the development of the majority of thyroid malignancies. The pathway is aberrantly activated primarily through mutually exclusive genetic alterations in the growth factor receptor RET, the three isoforms of RAS (N, H, K), and BRAF, one of which is present in ~70% of papillary thyroid carcinomas (PTCs).^{10,74-76} The BRAF^{V600E} mutation is the most common genetic alteration in papillary thyroid cancer.^{10,77}

Beyond promoting cellular proliferation and survival, oncogenic activation of MAPK signaling suppresses the expression of follicular cell-specific genes that are responsible for iodide uptake (e.g., the sodium-iodine symporter, or NIS) and metabolism.⁷⁸⁻⁸⁰ Additionally, each MAPK pathway alteration is also associated with different degrees of MAPK signaling output: BRAF-driven cancers possess higher MAPK output relative to RAS-driven cancers.⁸¹ The differential impact upon MAPK signaling output also translates to differences in suppression of thyroid differentiation. The Cancer Genome Atlas (TCGA) genomic analysis of almost 500 PTCs demonstrated that higher MAPK output tumors (e.g., “BRAF mutant cancer-like”) exhibit greater suppression of thyroid differentiation than other tumors (e.g., “RAS mutant cancer-like”).⁸² This biology provides the mechanistic basis of the well-established clinical observation that BRAF mutant tumors have a more aggressive clinical behavior and are more often RAI-refractory.⁸³⁻⁸⁵ In aggregate, these observations suggest that oncogenic MAPK pathway activation in thyroid malignancies diminishes iodide avidity by suppressing components of thyrocyte-specific gene expression; the extent to which this is achieved is determined by the specific MAPK pathway alteration.

MAPK pathway inhibition to enhance RAI avidity and efficacy

Experiments in cell line and animal models provided proof-of-principle data that pharmacologic manipulation of the MAPK pathway with small molecule inhibitors may be a novel approach for enhancing iodide avidity. In a mouse model of poorly differentiated thyroid cancer driven by inducible thyroid-specific expression of BRAF^{V600E}, treatment with downstream MAPK pathway inhibitors targeting either BRAF or MEK partially restored expression of NIS and iodine avidity.⁸⁶ These preclinical data led to a pilot clinical trial evaluating the impact of the MEK inhibitor Selumetinib upon iodide uptake in patients with RAI-refractory thyroid cancers.⁸⁷ In this study, recombinant human TSH (rh-TSH) I-124 PET/CT lesional dosimetry was utilized to quantify drug-induced changes in iodide

incorporation within specific lesions. Of the 20 evaluable patients, 12 (60%) had new or increased I-124 incorporation with Selumetinib. For 8 (40%) patients, the I-124 uptake predicted that > 2,000 cGy of I-131 could be delivered; these patients were treated with Selumetinib in combination with therapeutic I-131. These changes in iodide incorporation translated to clinical benefit, as all 8 patients treated with I-131 experienced reductions in tumor size. In total, there were 5 confirmed partial responses and 3 patients had stable disease. Substantial decreases in serum Tg were also achieved in all patients. This approach appeared to be particularly effective for patients harboring the *NRAS* mutation, as all five enrolled on the study qualified for treatment with I-131. By contrast, only one *BRAF* mutant patient received I-131 treatment. This pilot study provided a critical proof-of-concept that MAPK pathway inhibition can enhance RAI incorporation and efficacy in a subset of RAI-resistant patients. Much remains to be investigated in clinical trials before this approach can be introduced into regular clinical practice. The differences in efficacy observed within different genetic subsets of disease and the heterogeneity in the degrees of enhancement in iodide avidity achieved in the pilot study suggest that there is still opportunity to optimize pathway inhibition and restoration of thyrocyte-specific gene expression with alternative MAPK pathway inhibitors alone or in drug combinations. For *BRAF* mutant patients, treatment with a *BRAF* inhibitor may be a more promising approach: a recent pilot trial showed that Dabrafenib increased iodide incorporation in 6 of 10 *BRAF* mutant patients, resulting in tumor shrinkage after subsequent treatment with I-131 in 5 of the 6 patients (2 partial responses and 4 patients with stable disease).⁸⁸

Other targeted drugs

Romidepsin (a histone deacetylase inhibitor) has been studied in a group of 20 patients with RAI-resistant thyroid cancer. Restoration of radioiodine avidity was documented in 2 patients. No major RECIST responses were documented; stable disease was seen in 13 and progressive disease in 7 patients. This study had poor accrual after a grade 5 adverse event.⁸⁹ Another drug, Axitinib (a selective inhibitor of vascular endothelial growth factor receptors VEGFR 1, 2, and 3), was studied in 60 patients with advanced thyroid cancers in a multi-institutional phase 2 trial; partial responses were seen in 18 patients (30% objective response rate), and 38% patients showed stable disease at > or = 16 weeks.⁹⁰

In summary, although some of the data discussed in this section appear promising, optimizing and defining the efficacy and safety of various novel drugs will only be accomplished through larger prospective clinical trials. Imaging, including PET/CT with I-124 and FDG, as well as SPECT/CT with I-123 and I-131, will be a critical part of clinical trials and will be essential to guide and monitor novel targeted therapies. We expect these therapies will ultimately translate into improved outcomes for patients with advanced thyroid cancer over the next decade.

References

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid: official journal of the American Thyroid Association*. Nov; 2009 19(11):1167–1214. [PubMed: 19860577]

2. Wang LY, Nixon IJ, Palmer FL, et al. Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system? *Surgery*. Dec; 2014 156(6):1484–1489. discussion 1489–1490. [PubMed: 25456937]
3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. *The Journal of clinical endocrinology and metabolism*. Aug; 1990 71(2):414–424. [PubMed: 2380337]
4. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. *American journal of surgery*. Dec; 1996 172(6):692–694. [PubMed: 8988680]
5. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. *Annals of surgical oncology*. Feb; 2007 14(2):730–738. [PubMed: 17103065]
6. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *The American journal of medicine*. Nov; 1994 97(5):418–428. [PubMed: 7977430]
7. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. *Cancer*. Dec 15; 1998 83(12):2638–2648. [PubMed: 9874472]
8. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. *Cancer*. Mar 1; 2004 100(5):950–957. [PubMed: 14983490]
9. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. *Clinical cancer research: an official journal of the American Association for Cancer Research*. Dec 15; 2011 17(24):7511–7517. [PubMed: 21900390]
10. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer research*. Apr 1; 2003 63(7):1454–1457. [PubMed: 12670889]
11. Soares P, Lima J, Preto A, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. *Current genomics*. Dec; 2011 12(8):609–617. [PubMed: 22654560]
12. Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An (1)(8)F-FDG PET Study. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. May; 2015 56(5):662–667.
13. Maxon HR 3rd, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. *Endocrinology and metabolism clinics of North America*. Sep; 1990 19(3):685–718. [PubMed: 2261912]
14. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Jan; 2005 46(1):28s–37s.
15. Portulano C, Paroder-Belenitsky M, Carrasco N. The Na⁺/I⁻ symporter (NIS): mechanism and medical impact. *Endocrine reviews*. Feb; 2014 35(1):106–149. [PubMed: 24311738]
16. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *The Journal of clinical endocrinology and metabolism*. Aug; 2006 91(8):2892–2899. [PubMed: 16684830]
17. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L. Radioiodine Treatment of Metastatic Thyroid Cancer: Relative Efficacy and Side Effect Profile After Preparation by Thyroid Hormone Withdrawal vs. Recombinant Human TSH. *Thyroid: official journal of the American Thyroid Association*. Dec 22.2011
18. Klubo-Gwiedzinska J, Van Nostrand D, Atkins F, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. *The Journal of clinical endocrinology and metabolism*. Oct; 2011 96(10):3217–3225. [PubMed: 21849530]

19. Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. *The Journal of clinical endocrinology and metabolism*. May; 2013 98(5):E829–836. [PubMed: 23533233]
20. Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. *The Journal of clinical endocrinology and metabolism*. Jul; 2011 96(7):2105–2111. [PubMed: 21565788]
21. Hilts SV, Hellman D, Anderson J, Woolfenden J, Van Antwerp J, Patton D. Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Sep; 1979 20(9):928–932.
22. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Nov; 2002 43(11):1482–1488.
23. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. *The Journal of clinical endocrinology and metabolism*. Mar; 2006 91(3):926–932. [PubMed: 16384850]
24. Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. *The Journal of clinical endocrinology and metabolism*. May; 2015 100(5):1895–1902. [PubMed: 25734251]
25. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. *Cancer*. Jun 15; 1996 77(12):2574–2580. [PubMed: 8640708]
26. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? *European journal of nuclear medicine*. 1987; 12(10):500–502. [PubMed: 3569338]
27. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Feb; 1991 32(2): 252–254.
28. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. *PloS one*. 2008; 3(4):e1885. [PubMed: 18382668]
29. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *The American journal of roentgenology, radium therapy, and nuclear medicine*. Jan.1962 87:171–182.
30. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Oct; 2006 47(10):1587–1591.
31. Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. *Thyroid: official journal of the American Thyroid Association*. Oct; 2006 16(10):1019–1023. [PubMed: 17042688]
32. Fatourehchi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? *Thyroid: official journal of the American Thyroid Association*. Jul; 2000 10(7):573–577. [PubMed: 10958309]
33. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. *The Journal of clinical endocrinology and metabolism*. Mar; 1994 78(3):629–634. [PubMed: 8126134]
34. Souza Rosario PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? *Clinical nuclear medicine*. Dec; 2004 29(12):795–798. [PubMed: 15545881]
35. Grewal RK, Tuttle RM, Fox J, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Sep; 2010 51(9):1361–1367.

36. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of ¹³¹I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Jan; 2009 50(1):18–23.
37. Mustafa M, Kuwert T, Weber K, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. *European journal of nuclear medicine and molecular imaging*. Aug; 2010 37(8):1462–1466. [PubMed: 20358197]
38. Maruoka Y, Abe K, Baba S, et al. Incremental diagnostic value of SPECT/CT with ¹³¹I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. *Radiology*. Dec; 2012 265(3):902–909. [PubMed: 23012466]
39. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Mar; 2003 44(3):451–456.
40. Maxon HR 3rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Jun; 1992 33(6):1132–1136.
41. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *The New England journal of medicine*. Oct 20; 1983 309(16):937–941. [PubMed: 6621620]
42. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. *Medical physics*. Jul-Aug; 1976 03(04):253–255. [PubMed: 958163]
43. Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Jan; 1999 40(1):131–136.
44. Erdi YE, Macapinlac H, Larson SM, et al. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. *Clinical positron imaging: official journal of the Institute for Clinical PET*. Jan; 1999 2(1):41–46.
45. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Dec; 1987 28(12):1888–1891.
46. Iwano S, Kato K, Nihashi T, Ito S, Tachi Y, Naganawa S. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. *Annals of nuclear medicine*. Nov; 2009 23(9):777–782. [PubMed: 19787312]
47. Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. *International journal of radiation oncology, biology, physics*. Mar 1; 2009 73(3):795–801.
48. Romesser PB, Sherman EJ, Shaha AR, et al. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. *Journal of surgical oncology*. Sep; 2014 110(4):375–382. [PubMed: 24961938]
49. Grewal, RK.; Lubberink, M.; Pentlow, KS.; Larson, SM. The role of Iodine -124-Positron Emission Tomography imaging in the management of patients with thyroid cancer. Vol. 2. Pennsylvania: W.B. Saunders Company; 2008.
50. Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). *Cancer biotherapy & radiopharmaceuticals*. Jun; 2007 22(3):423–430. [PubMed: 17651050]
51. Phan HT, Jager PL, Paans AM, et al. The diagnostic value of ¹²⁴I-PET in patients with differentiated thyroid cancer. *European journal of nuclear medicine and molecular imaging*. May; 2008 35(5):958–965. [PubMed: 18175115]
52. Van Nostrand D, Moreau S, Bandaru VV, et al. (¹²⁴I) positron emission tomography versus (¹³¹I) planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. *Thyroid: official journal of the American Thyroid Association*. Aug; 2010 20(8):879–883. [PubMed: 20615132]

53. de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. (1)(2)(4)I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy (1)(3)(1)I SPECT/CT. *European journal of nuclear medicine and molecular imaging*. May; 2013 40(5):693–700. [PubMed: 23340593]
54. Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of (124)I with PET/CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. *The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. Feb*; 2011 55(1):21–43.
55. Jentzen W, Hoppenbrouwers J, van Leeuwen P, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Nov; 2014 55(11):1759–1765.
56. Freudenberg LS, Jentzen W, Gorges R, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. *Nuklearmedizin Nuclear medicine*. 2007; 46(4):121–128. [PubMed: 17690789]
57. Pettinato C, Spezi E, Nanni C, et al. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning. *Clinical nuclear medicine*. Aug; 2014 39(8):e367–374. [PubMed: 24978332]
58. Khorjekar GR, Van Nostrand D, Garcia C, et al. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans? *Thyroid: official journal of the American Thyroid Association*. Sep; 2014 24(9):1394–1399. [PubMed: 24820222]
59. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Sep; 1996 37(9):1468–1472.
60. Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake. *Nuklearmedizin Nuclear medicine*. 2013; 52(4):121–129. [PubMed: 23928981]
61. Al-Nahhas A, Khan S, Gogbashian A, Banti E, Rampin L, Rubello D. Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy. *In vivo (Athens, Greece)*. Jan-Feb; 2008 22(1):109–114.
62. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. *Cancer*. Jul 1; 2008 113(1):48–56. [PubMed: 18484584]
63. Poisson T, Deandreis D, Leboulleux S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. *European journal of nuclear medicine and molecular imaging*. Dec; 2010 37(12):2277–2285. [PubMed: 20694463]
64. Wang W, Larson SM, Tuttle RM, et al. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. *Thyroid: official journal of the American Thyroid Association*. Dec; 2001 11(12):1169–1175. [PubMed: 12186505]
65. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. *The Journal of clinical endocrinology and metabolism*. Mar; 2000 85(3):1107–1113. [PubMed: 10720047]
66. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Jan; 2001 42(1):71–76.
67. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *The Journal of clinical endocrinology and metabolism*. Feb; 2006 91(2):498–505. [PubMed: 16303836]
68. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. Oct; 2001 42(10):1464–1469.

69. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. *European journal of nuclear medicine*. Dec; 1999 26(12):1547–1552. [PubMed: 10638405]
70. Nascimento C, Borget I, Al Ghuzlan A, et al. Post-operative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT): an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. *Thyroid: official journal of the American Thyroid Association*. Jan 29.2015
71. Braga-Basaria M, Ringel MD. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. *The Journal of clinical endocrinology and metabolism*. May; 2003 88(5):1947–1960. [PubMed: 12727938]
72. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet*. Jul 26; 2014 384(9940):319–328. [PubMed: 24768112]
73. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *The New England journal of medicine*. Feb 12; 2015 372(7):621–630. [PubMed: 25671254]
74. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. *Journal of the National Cancer Institute*. Apr 16; 2003 95(8):625–627. [PubMed: 12697856]
75. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. *Oncogene*. Jul 17; 2003 22(29):4578–4580. [PubMed: 12881714]
76. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. *Current opinion in cell biology*. Apr; 2009 21(2):296–303. [PubMed: 19231149]
77. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. *Cancer research*. Jun 1; 2009 69(11):4885–4893. [PubMed: 19487299]
78. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *The Journal of clinical endocrinology and metabolism*. Jul; 2007 92(7):2840–2843. [PubMed: 17488796]
79. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. *Clinical cancer research: an official journal of the American Association for Cancer Research*. Feb 15; 2007 13(4):1341–1349. [PubMed: 17317846]
80. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻ targeting to the membrane. *Endocrine-related cancer*. Mar; 2006 13(1):257–269. [PubMed: 16601293]
81. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proceedings of the National Academy of Sciences of the United States of America*. Mar 17; 2009 106(11):4519–4524. [PubMed: 19251651]
82. Integrated genomic characterization of papillary thyroid carcinoma. *Cell*. Oct 23; 2014 159(3):676–690. [PubMed: 25417114]
83. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. *The Journal of clinical endocrinology and metabolism*. Oct; 2008 93(10):3943–3949. [PubMed: 18682506]
84. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. *Cancer*. Jul 1; 2007 110(1):38–46. [PubMed: 17520704]
85. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *Jama*. Apr 10; 2013 309(14):1493–1501. [PubMed: 23571588]

86. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. *The Journal of clinical investigation*. Dec; 2011 121(12):4700–4711. [PubMed: 22105174]
87. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. *The New England journal of medicine*. Feb 14; 2013 368(7):623–632. [PubMed: 23406027]
88. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. *Clinical cancer research: an official journal of the American Association for Cancer Research*. Mar 1; 2015 21(5):1028–1035. [PubMed: 25549723]
89. Sherman EJ, Su YB, Lyall A, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. *Thyroid: official journal of the American Thyroid Association*. May; 2013 23(5):593–599. [PubMed: 23186033]
90. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Oct 10; 2008 26(29):4708–4713. [PubMed: 18541897]

Figure 1.
I124 PET MIP scan showing uptake in multiple bone metastases. I131 Post therapy scan done about 4 years earlier showed uptake in a few bone metastases

Figure 2.

A: Flip flop phenomenon showing multiple FDG avid lung metastases which are not iodine avid on I124 PET scan.

B: Flip flop phenomenon showing multiple FDG avid lung metastases which are not iodine avid. Top row transaxial images are FDG PET and bottom row transaxial images are I124 PET.

Figure 3.

A: FDG PET MIP scan shows uptake in left tracheo-esophageal groove mass, lung, thoracic nodal and osseous metastases

B: FDG PET show uptake in lung, thoracic nodal and osseous metastases

SIGNALING PATHWAYS IN THYROID CANCER

Figure 4.